Moderna, Inc. Finance Lease, Liability, to be Paid, after Year Five
Moderna, Inc. (MRNA) had Finance Lease, Liability, to be Paid, after Year Five of $428.06 million as of 2020-12-31, per its 10-K filed 2021-02-26.
Discontinued › Notes › Commitment and Contingencies › Finance Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive · last filed 2021-02-26
- 2020-12-31: Finance Lease, Liability, to be Paid, after Year Five $428.06M.
- 2020-03-31: Finance Lease, Liability, to be Paid, after Year Five $264.16M.
- 2019-12-31: Finance Lease, Liability, to be Paid, after Year Five $264.16M.
| Period end | Finance Lease, Liability, to be Paid, after Year Five |
|---|---|
| 2020-12-31 | $428.06M 10-K · filed 2021-02-26 |
| 2020-03-31 | $264.16M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $264.16M 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |